Hypothesis Statement\nWe hypothesize that the rate of mitochondrial fatty‑acid oxidation (FAO) controlled by carnitine palmitoyltransferase‑1 (CPT1) functions as an upstream controller that links primary DNA damage to multiple downstream hallmarks of aging. By modulating acetyl‑CoA production, CPT1‑FAO sets the epigenetic tone that drives senescence‑associated secretory phenotype (SASP), inflammaging, stem‑cell exhaustion, and epigenetic drift.\n\n## Mechanistic Rationale\n1. DNA damage → FAO activation – ATM‑dependent signaling upregulates CPT1 expression and FAO flux, increasing mitochondrial acetyl‑CoA (see 2).\n2. Acetyl‑CoA → histone acetylation – Elevated acetyl‑CoA fuels histone acetyltransferases, raising H3K27ac at promoters of p16^INK4a and SASP genes (IL‑6, IL‑8, MCP‑1), thereby locking cells into a senescent state.\n3. FAO ↔ NAD+/NADH ratio – High FAO lowers NAD+ availability, dampening sirtuin‑mediated deacetylation and reinforcing a hyper‑acetylated chromatin landscape.\n4. Feedback loop – SASP cytokines reinforce ATM signaling in neighboring cells, propagating FAO‑driven epigenomic changes across tissues.\nThus, CPT1‑FAO sits at a nexus where genomic instability (primary hallmark) is translated into antagonistic (mitochondrial dysfunction) and integrative (senescence, inflammaging) hallmarks.\n\n## Testable Predictions\n- Prediction 1: Inducible, tissue‑specific CPT1 knockout or pharmacological inhibition (etomoxir) in mice aged 20‑24 months will simultaneously reduce senescence markers (SA‑β‑gal, p16^INK4a), circulating inflammatory cytokines (IL‑6, TNF‑α), stem‑cell exhaustion (colony‑forming units), and age‑related epigenetic drift (DNA methylation clocks) without altering plasma carnitine levels.\n- Prediction 2: In human fibroblasts exposed to ionizing radiation, CRISPR‑mediated CPT1 knock‑down will decrease mitochondrial acetyl‑CoA (measured by LC‑MS), lower H3K27ac at SASP promoters (ChIP‑qPCR), and suppress SASP secretion (ELISA).\n- Prediction 3: Supplementation with acetate or acetyl‑CoA precursors will rescue the SASP phenotype in CPT1‑deficient cells, confirming that the metabolite, not the enzyme per se, drives the epigenetic effect.\n- Prediction 4: Long‑term CPT1 inhibition will maintain basal ATP production via upregulated glycolysis (Seahorse ECAR increase) and preserve mitochondrial membrane potential, indicating that energetic failure is not a confounding factor.\n\n## Experimental Approach\n- Animal model: Use CPT1^fl/fl mice crossed with inducible Cre‑ER lines (e.g., Vav‑Cre‑ER for hematopoietic cells, HSA‑Cre‑ER for skeletal muscle). Administer tamoxifen at 18 months, then treat half with etomoxir (5 mg/kg/day) for 3 months. Controls receive vehicle.\n- Readouts:\n - Senescence: SA‑β‑gal staining, p16^INK4a and p21 mRNA (qPCR).\n - Inflammaging: Plasma cytokine multiplex, tissue SASP RNA‑seq.\n - Stem‑cell function: Competitive transplantation assays, colony‑forming unit counts.\n - Epigenetic state: Whole‑genome bisulfite sequencing (DNAmAge), ATAC‑seq, H3K27ac ChIP‑seq.\n - Metabolomics: Targeted LC‑MS for acetyl‑CoA, NAD+/NADH.\n - Bioenergetics: Seahorse XF analysis (OCR, ECAR).\n- In vitro validation: Primary human fibroblasts irradiated (2 Gy), transfected with CPT1 siRNA or treated with etomoxir (40 µM). Measure acetyl‑CoA, histone acetylation, SASP secretion, and rescue with sodium acetate (5 mM).\n\n## Potential Outcomes and Falsification\n- Supportive outcome: Significant improvement across ≥3 hallmarks in CPT1‑deficient/ inhibited animals, accompanied by reduced acetyl‑CoA and histone acetylation at SASP loci, and reversal by acetate supplementation. This would substantiate CPT1‑FAO as an upstream controller.\n- Falsifying outcome: Inhibition of CPT1 alters only one hallmark (e.g., reduces senescence but leaves inflammaging and epigenetic drift unchanged) or produces no measurable benefit despite clear target engagement. Such results would argue against a single upstream metabolic regulator and favor a more parallel, damage‑centric view of aging.\n\n## Broader Implications\nIf validated, targeting the CPT1‑FAO axis—preferably with intermittent or tissue‑specific inhibition—could decouple DNA damage from its deleterious downstream effects, offering a unified intervention strategy that attenuates multiple age‑related pathologies without requiring global metabolic suppression.